Registration Webcast Header

Olink Investor Day 2021

Already Registered?

Log in Now

About

Start date: 11/15/2021
Start time:
New York: 12:30 PM EST
London: 5:30PM GMT
Stockholm: 6:30PM CET
Duration: 180 minutes
Welcome to the Olink Investor Day on November 15th, 2021. We will provide direct access to key opinion leaders from leading universities and BioPharma companies, while offering an update on exciting research projects where Olink is a proud contributor. The program includes fireside chats with leaders in cardiology, immunology, oncology, dermatology and neurology, who will share their perspectives on proteomics and how they use our technology and products to advance their research. You will also hear the latest from the UK Biobank Pharma Proteomics Project, currently performing one of the world’s largest scientific studies of plasma protein biomarkers conducted to date. In addition, we will provide an update on our commercial plans.

Speakers

Professor Robert E. Gerszten, M.D.

Chief of Cardiology

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA

Robert E. Gerszten, MD is Chief of Cardiology at Beth Israel Deaconess Medical Center, the Herman Dana Professor of Medicine at Harvard Medical School, and a Senior Associate Member of the Broad Institute. Dr. Gerszten graduated from the Johns Hopkins University School of Medicine. He completed his residency at the Hospital of the University of Pennsylvania and a clinical fellowship in cardiology at Massachusetts General Hospital (MGH). He also performed research fellowships at the Cardiovascular Research Institute at the University of California, San Francisco and the Cardiovascular Research Center at MGH. Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases. His translational research program leverages metabolomics and proteomic technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study, the Jackson Heart Study, the Diabetes Prevention Program, and the TIMI Study Group. His work has been funded by the NIH and the American Heart Association, from whom he received an Established Investigator Award. Dr. Gerszten is a member of the American Society for Clinical Investigation, the Association of American Physicians, and the Association of University Cardiologists.

Professor Emma Guttman -Yassky, M.D., Ph.D.

System Chair of the Department of Dermatology

Icahn School of Medicine at Mount Sinai, New York, NY

Dr. Guttman-Yassky, MD, PhD is the System Chair of the Department of Dermatology, and the Waldman Professor of Dermatology and Immunology at the Icahn School of Medicine at Mount Sinai, New York. She is the Director of the Center for Excellence in Eczema and the Laboratory for Inflammatory Skin Diseases. She earned her M.D. from the Sackler Faculty of Medicine at Tel-Aviv University in Israel, and a Ph.D. from Bar-Ilan University in Ramat Gan, Israel. After receiving her Israeli board certification in dermatology, she moved to the United States to pursue a postdoctoral fellowship at The Rockefeller University and a second dermatology residency at Weill Cornell Medicine, both in New York. Her major focus is atopic dermatitis (AD). She made paradigm-shifting discoveries on the immunologic basis of AD in humans, enriching the understanding of its pathophysiology and opening the door to new AD therapeutics. She has developed comprehensive molecular maps of AD, defining skin differentiation and immune circuits characterizing the disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel, pathway-specific drugs for AD. Recently she has extended her research interest to alopecia areata; her findings in that area are also being translated into possible novel therapeutic targets. Dr. Guttman-Yassky cofounded and serves as president-elect of the International Eczema Council, and was elected to the American Society for Clinical Investigation and the American Dermatological Association. She received the Young Investigator Award from the American Academy of Dermatology in 2011.

Ferhan Qureshi

VP of Biomarker Product Development

Octave Bioscience, Inc.

Ferhan Qureshi has over 20 years of experience at biotechnology companies in the San Francisco Bay Area including roles at Genentech, Aviir, Crescendo Bioscience, and now Octave leading cross-functional teams involved in the R&D of analytical techniques to support therapeutic development and in-vitro diagnostic applications. Ferhan has been directly involved with several successful cutting-edge projects with a primary focus on multiplex immunoassay techniques deployed within regulated environments (GLP/CLIA) to support products in oncology, cardiovascular, autoimmune and neurodegenerative diseases. About Octave Bioscience: At Octave, we believe knowledge is power. Our fully integrated Multiple Sclerosis care management solution is designed to provide neurologists and their patients with objective metrics to facilitate informed care and shared decision making for better patient outcomes. It provides multiple layers of insights including MRI analytics, patient-centered remote monitoring tools and a blood-based Multiple Sclerosis disease activity (MSDA) test. Octave partnered with Olink to develop and validate the MSDA test and is continuing to use the platform for deep-scan proteomics to support future product development efforts in MS and other neurodegenerative diseases.

Dr. Arnav Mehta, M.D., Ph.D.

Postdoctoral researcher

Broad Institute of MIT and Harvard, Boston, MA

Dr. Mehta is an oncologist, immunologist, and mathematician who is currently a postdoctoral researcher in Nir Hacohen and Eric Lander’s labs at the Broad Institute of MIT and Harvard, and a clinical fellow in hematology/oncology at the Dana-Farber Cancer Institute/Partners CancerCare. Prior to his current position, he obtained his undergraduate degrees at Duke University studying mathematics and chemistry, his M.D. at the David Geffen School of Medicine at the University of California, Los Angeles, and his Ph.D. in biology and bioengineering at the California Institute of Technology under the guidance of Nobel laureate David Baltimore. He completed his internal medicine residency at Massachusetts General Hospital in the Stanbury Physician-Scientist Pathway program. His current interests lie at the intersection of tumor immunology and computational biology, with a focus on building new tools for single-cell genomics studies in tumors.

Dr. Chris Whelan, Ph.D.

Associate Director, Head of Translational Genetics

Biogen R&D, Cambridge, MA

Dr. Whelan is Associate Director and Head of Translational Genetics at Biogen R&D. He received his Ph.D. from the Royal College of Surgeons in Dublin, Ireland in 2014 and completed a postdoctoral fellowship in 2016 with the ENIGMA consortium, based at the University of Southern California. His graduate and postdoctoral research focused on the combination of genome-wide association data with magnetic resonance imaging scans, leading to the world’s largest studies of genetic susceptibility to epilepsy (Whelan/International League Against Epilepsy Consortium on Complex Epilepsies, Lancet Neurology,2014), genetic determinants of subcortical brain volumes (Hibar et al., Nature, 2015), and changes in brain structure within and across the common epilepsies (Whelan et al., Brain, 2018). In 2016, he joined the Genome Sciences & Technologies group at Pfizer as a manager of human genetics, where he served as the scientific strategy lead for Neuroscience Genetics. Dr. Whelan moved to Biogen in 2018, where his research has focused on applying quantitative genetics, biomarker discovery, and advanced neuroimaging to help accelerate drug discovery programs and integrate precision medicine strategies for Alzheimer’s disease and epilepsy. Dr. Whelan is also Chairman of the UK Biobank Pharma Proteomics Project. The UK Biobank Pharma Proteomics Project (UKB-PPP) is a partnership between UK Biobank and a biopharmaceutical consortium, currently performing one of the world’s largest scientific studies of plasma protein biomarkers conducted to date of 54,000 UK Biobank participants. The study aims to enable better understanding of disease biology and support innovative drug development for more effective therapies. Initially funded by ten biopharmaceutical companies, the consortium has now grown to twelve companies, further emphasizing the value of this important work.

Jon Heimer

Chief Executive Officer

Olink Proteomics AB

Jon Heimer has served as the chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of our Board of Directors since December 2020. From April 2011 until December 2015, Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990’s and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.

Carl Raimond

Chief Commercial Officer

Olink Proteomics AB

Carl Raimond has served as Chief Commercial Officer since October 2020, and previously served as Senior Vice President of Sales beginning in August 2020. Prior to joining Olink, from January 2015 until February 2020, Mr. Raimond served in various executive commercial leadership roles at PerkinElmer, Inc. including Vice President and General Manager of Americas Sales and Service and Global Vice President and General Manager of Sales and Service for the Discovery and Analytical Solutions Division. From June 2010 until January 2015, Mr. Raimond served as the Vice President and General Manager of the Americas Life Science Sales & Field Operations of Agilent Technologies, Inc. Mr. Raimond received his Bachelor of Arts in zoology from State University of New York College at Oswego, and his Master of Science in biology from State University of New York College at Brockport.

Dr. Ida Grundberg, Ph.D.

Chief Scientific Officer

Olink Proteomics AB

Ida Grundberg, PhD has served as Chief Scientific Officer since September 2019. From September 2011 until September 2019, Dr. Grundberg served in various roles, including Senior Scientist, Project Manager, Business Development Manager, Head of Business Development for North America, and Vice President of Sales and Marketing for North America. Dr. Grundberg received her Bachelor of Science from Umeå University, her Master of Science in molecular biology from Umeå University, and her PhD in molecular medicine from Uppsala University.

Oskar Hjelm

Chief Financial Officer

Olink Proteomics AB

Oskar Hjelm has served as Chief Financial Officer since March 2020. Prior to joining Olink, from September 2017 until February 2020, Mr. Hjelm worked at Alvarez & Marsal Sweden AB within its Transaction Advisory Group providing support to European and Nordic private equity funds. From August 2016 until August 2017, Mr. Hjelm was a director at KPMG AB. From January 2016 until August 2016, Mr. Hjelm was an investment controller at Nordic Capital. From July 2008 until December 2015, Mr. Hjelm held various roles at KPMG AB and KPMG LLP (United Kingdom). Mr. Hjelm received his Master of Science in business and economics from Linköping University.

Jan Medina, CFA

VP IR & Capital Markets

Olink Proteomics AB

Jan Medina has served as VP, IR & Capital Markets since October 2021. Prior to joining Olink, he was Director, IR at the I-O BioPharma, Agenus. His additional IR experience includes positions at HC-focused agencies The Ruth Group, Russo Partners, and Noonan/Russo. Jan’s sell-side experience includes roles at Cross Current Research, Coleman Research, ABN AMRO, CSFB, Deutsche Bank, and DLJ. On the buy-side, Jan focused on HC as well, and has worked in strategic and transaction advisory as a consultant to life sciences companies. Jan holds a Bachelor of Science in Biomedical Engineering from Tulane University in New Orleans, Louisiana.

Register Today

First Name
Last Name
Job Title
Company
City
Country
Time Zone
Email Address